President Donald Trump unveiled a groundbreaking deal that promises to significantly reduce the cost of obesity medications, potentially transforming healthcare access for millions of Americans, especially seniors on Medicare.
The agreement with pharmaceutical giants Eli Lilly and Novo Nordisk will lower prices for popular GLP-1 drugs like Wegovy and Zepbound to between $149 and $350 per month, down from exorbitant costs exceeding $1,000.
This initiative, part of Trump's “TrumpRx” program, marks the first time Medicare will cover obesity drugs, aiming to tackle the obesity crisis head-on by making vital treatments affordable.
During the announcement, a poignant moment occurred when a Novo Nordisk executive fainted in the Oval Office, drawing media attention and sparking lively discussions across news platforms.
While the deal is celebrated for expanding access, some experts caution about the long-term effectiveness of such drugs, as many users tend to regain weight after discontinuation.
The public reaction to the deal has been mixed, highlighting optimism for increased accessibility while raising concerns about the sustainability of reduced prices and the broader implications for healthcare quality.
Top Keywords
Donald Trump/Robert F. Kennedy Jr./Dr. Oz/Gordon Findlay/Washington, United States/Medicare/Eli Lilly/Novo Nordisk/
99
